Getting removed from the National Donor Deferral Registry is rare but not impossible. If a plasma screening test flagged you as reactive for HIV, hepatitis B, or hepatitis C, your path back runs through the plasma center that reported you — not through PPTA, not through FDA, and not through any central office. The center holds your test records and is the only entity that can pursue requalification on your behalf under the federal regulation that governs donor reentry.
PPTA is direct about the odds: donors are rarely removed from the NDDR. The registry exists to keep potentially infectious plasma out of the therapies manufactured from the U.S. and Canadian donor supply, and that safety purpose takes priority over individual eligibility. But “rarely” is not “never,” and federal regulation does provide a pathway.
Start With the Center That Reported You
Every removal case begins with the plasma collection facility where you donated when the reactive test occurred. That center holds your screening results, any confirmatory testing, and the deferral record itself. Contact them directly and ask to speak with someone who handles donor deferral questions.
If you don’t remember which center reported you, or if you donated at more than one location, PPTA provides an “Information for Donors Found in the NDDR” form on its website that helps identify the reporting center. Do not try to route your request through PPTA itself. Its website states plainly that PPTA has “no ability to access the NDDR or advocate on your behalf.” Inquiries about your individual status must go through the reporting center.1Plasma Protein Therapeutics Association. National Donor Deferral Registry
When you make contact, ask for:
- The results of the initial reactive screening test.
- The results of any supplemental or confirmatory testing performed on the same donation.
- Written confirmation of the deferral and the reason for it.
Keep records of every call, email, and letter, including dates and the names of the staff you spoke with. If the center is slow or unresponsive, that documentation matters later.
Why Your Confirmatory Test Results Matter
Screening tests used at plasma centers are built to be extremely sensitive, which means they occasionally produce false positives. A reactive screening triggers your NDDR entry, but the follow-up testing is what determines whether the initial result reflected an actual infection.
Federal regulations require that every reactive donation undergo further testing using a licensed supplemental test, or if none is available, one or more additional tests that provide further information about the donor’s infection status.2eCFR. 21 CFR 610.41 – Donor Deferral For hepatitis C, for example, if a nucleic acid test with a supplemental indication comes back nonreactive and a second, different test also comes back negative, FDA guidance says the donor should be counseled that HCV infection was not confirmed and is unlikely. That kind of confirmatory outcome is the strongest foundation for a removal request, because it points to a false-positive screening.
Centers are required to make reasonable attempts to notify donors of a deferral within eight weeks of the determination. If you never received that notification, or if confirmatory testing was never completed, say so when you contact the center. Incomplete follow-up can be relevant to your case.
The FDA Requalification Pathway
The legal basis for getting off the NDDR is in 21 CFR 610.41(b), which states that a deferred donor “may be found to be eligible as a donor of blood or blood components by a requalification method or process found acceptable for such purposes by FDA.” A donor who successfully completes that process “is considered no longer deferred.”2eCFR. 21 CFR 610.41 – Donor Deferral
In practice, that means the plasma center has to apply an FDA-recognized requalification protocol to your case. FDA has issued guidance for requalification of donors deferred for reactive anti-HBc (hepatitis B core antibody) results, laying out how a center can determine that a previous reactive test was falsely positive and that there is no evidence of HBV infection.3U.S. Food and Drug Administration. Requalification Method for Reentry of Blood Donors Deferred Because of Reactive Test Results for Antibody Whether an equivalent pathway exists for other markers depends on the specific virus and the current state of FDA guidance when you pursue removal.
You cannot requalify yourself. The center must apply the FDA-acceptable method, and many centers have little incentive to invest that effort for a single donor. If the reporting center declines, your options are to be persistent, ask whether another participating center will evaluate your case, or consult an attorney who handles healthcare regulatory matters.
Narrow Exceptions That Allow Limited Donation
Even while listed on the NDDR, a few product-specific exceptions in federal regulation may allow certain limited donations. A donor who tested reactive for HBsAg (hepatitis B surface antigen) but currently tests nonreactive may be eligible to donate source plasma for the manufacture of Hepatitis B Immune Globulin. Donors reactive for anti-HBc or HTLV may still be eligible to donate source plasma if they are otherwise determined eligible.2eCFR. 21 CFR 610.41 – Donor Deferral
These exceptions are narrow and tied to specific products. They don’t amount to full removal from the NDDR, but if one fits your situation, raise it with the reporting center.
What the NDDR Does Not Affect
Being listed on the NDDR does not prevent you from registering as an organ donor, joining a bone marrow registry, or donating blood outside the plasma industry’s IQPP program, though separate FDA deferral rules apply to blood donation. The NDDR also is not visible to insurers, employers, or background-check services; participating plasma collectors can only query whether a specific donor is listed, and the registry contains identifying information without test results attached.1Plasma Protein Therapeutics Association. National Donor Deferral Registry
A Realistic Plan
The order of operations is straightforward, even if the outcome is uncertain:
- Contact the reporting center and ask for a full copy of your screening and confirmatory test results in writing.
- Read those results carefully. If confirmatory testing was nonreactive or the follow-up work was never completed, those are the facts that support a removal request.
- Ask the center directly whether it will pursue requalification under 21 CFR 610.41(b) and, where applicable, the FDA guidance for the specific marker involved.
- If the center refuses or stalls, document the refusal, ask for it in writing, and consider consulting a healthcare regulatory attorney about next steps.
Removal is rare because the registry is designed to be conservative, not because the pathway does not exist. Get your test results in hand first. Everything after that depends on what they show and how willing the reporting center is to work the requalification process on your behalf.